secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001159036-23-000006
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme elects Barbara Duncan to Board of Directors; Audit Committee assignment
--------------------------------------------------------------------------------

- Barbara Duncan elected to Board on Feb 3, 2023, with term expiring at 2024 annual meeting.
- Initially assigned to serve on the Audit Committee.
- Compensation follows non-employee director program; no related-party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000006/0001159036-23-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000006/halo-20230203.htm
  HTML page:      https://secwatch.observer/filing/0001159036-23-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer